TEL AVIV, Israel, Jan. 6, 2022 /PRNewswire/ -- SciSparc Ltd.
(NASDAQ: SPRC) (the "Company"), a clinical-stage pharmaceutical
company focusing on the development of therapies to treat disorders
of the central nervous system, today announced that The Israeli
Medical Center for Alzheimer's has recruited the first patient to
participate in the Company's Phase IIa clinical trial that will
evaluate the safety, tolerability and efficacy of SCI-110 in
patients with Alzheimer's disease and agitation using the Company's
proprietary cannabinoid-based technology.
The trial's primary objective is evaluating the safety of
SCI-110 and the secondary objective is evaluating the ability of
the compound to ameliorate agitation and other behavioral
disturbances in patients with Alzheimer's disease.
The trial, titled "Clinical Study Protocol Phase II-a open label
trial to evaluate the safety, tolerability and efficacy trend of
SCI-110 in patients with Alzheimer Disease and agitation," will be
conducted at the Sophie & Abraham Stuchynski Israeli
Alzheimer's Medical Center, Ramat-Gan, Israel.
The drug product SCI-110 is a unique proprietary combination of
Dronabinol (synthetic delta-9-tetrahydrocannabinol (Δ⁹-THC), and
Palmitoylethanolamide (PEA).
Alzheimer's disease is the most common type of dementia,
accounting for over two-thirds of cases of dementia. Alzheimer's
disease is a neurodegenerative disease that causes progressive and
disabling impairment of cognitive functions, including memory,
comprehension, language, attention, reasoning and judgment.
Symptoms of Alzheimer's disease depend on the stage of the disease.
Neuropsychiatric symptoms like apathy, social withdrawal,
disinhibition, agitation, psychosis, insomnia, poor appetite and
wandering are also common in the mid to late stages. Agitation is
common in nearly 60% of patients with dementia, increases caretaker
burden, creates safety risk for individuals with dementia and
others and increases risk for hospitalization and nursing home
placement. The current pharmacological treatment of agitation in
Alzheimer's disease has an unsatisfactory benefit/risk ratio and
often involves using off-label drugs. Antipsychotic drugs, which
are the most frequently used drugs for this purpose, are only
marginally better than placebo. Moreover, the U.S. Food and Drug
Administration has placed a "black box" warning on some of these
drugs describing the risks.
"We are excited to achieve this important milestone of
recruiting the first patient for our Phase IIa clinical trial. As
the population of the world continues to age, Alzheimer's disease
is one of the most common diseases affecting the elderly, and
subsequently the number of patients suffering from agitation also
dramatically increases. Unfortunately, patients have very limited
efficient treatments available today and those available can cause
side effects, like drowsiness, rigidity and unusual movements.
Studies have linked some of these to a higher risk of death for
people with dementia. We are hoping our innovative treatment will
provide patients and their families, with an efficient treatment
option," said Dr. Adi Zuloff-Shani, PhD, Chief Technology Officer
of the Company.
About SciSparc (NASDAQ: SPRC):
SciSparc Ltd. is a specialty clinical-stage pharmaceutical
company led by an experienced team of senior executives and
scientists. Our focus is on creating and enhancing a portfolio of
technologies and assets based on cannabinoid pharmaceuticals. With
this focus, the Company is currently engaged in the following drug
development programs based on THC and/or non-psychoactive
cannabidiol (CBD): SCI-110 for the treatment of Tourette syndrome,
for the treatment of obstructive sleep apnea and Alzheimer's
disease and agitation; SCI-160 for the treatment of pain; and
SCI-210 for the treatment of autism spectrum disorder and
epilepsy.
About The Israeli Medical Center for Alzheimer's:
The Israeli Medical Center for Alzheimer's (IMCA) is the only
medical center in Israel
exclusively devoted to the treatment of Alzheimer's disease
patients. IMCA was founded in 1994 as a public, not for profit
foundation, and in July 2001 it
opened as an active medical center. The IMCA treats hundreds of
patients a year, as inpatients, outpatients and as part of its
diagnosis and counseling services. Numerous studies are conducted
at the center in collaboration with researchers at universities.
Forward-Looking Statements:
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995 and other Federal
securities laws. For example, SciSparc is using forward-looking
statements when it discusses the potential safety, tolerability and
efficacy of SCI-110 in patients with Alzheimer's disease and
agitation. The transaction described here may never be consummated
and definitive agreement(s) may not be executed, and, if executed,
such agreement(s) may be subject to conditions before it can be
completed. In addition, the market for products contemplated by the
letter of intent is in a period of regulatory and business
uncertainty and financial and business results from such businesses
are uncertain. Historic results of scientific research and clinical
and preclinical trials do not guarantee that the conclusions of
future research or trials will suggest identical or even similar
conclusions. Because such statements deal with future events and
are based on SciSparc's current expectations, they are subject to
various risks and uncertainties and actual results, performance or
achievements of SciSparc could differ materially from those
described in or implied by the statements in this press release.
The forward-looking statements contained or implied in this press
release are subject to other risks and uncertainties, including
those discussed under the heading "Risk Factors" in SciSparc's
Annual Report on Form 20-F filed with the SEC on March 30, 2021, and in subsequent filings with
the U.S. Securities and Exchange Commission. Except as otherwise
required by law, SciSparc disclaims any intention or obligation to
update or revise any forward-looking statements, which speak only
as of the date they were made, whether as a result of new
information, future events or circumstances or otherwise.
Investor Contact:
IR@scisparc.com
Tel: +972-3-6167055
Logo -
https://mma.prnewswire.com/media/1434686/SciSparc_Ltd_Logo.jpg
View original content to download
multimedia:https://www.prnewswire.com/news-releases/scisparc-announces-recruitment-of-first-patient-for-its-phase-iia-clinical-trial-in-alzheimers-disease-301455472.html
SOURCE SciSparc Ltd.